Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

PIRS

Pieris Pharmaceuticals Inc

May 17 • 04:00PM ET

10.97

Dollar change -0.28
Percentage change -2.49	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.74	Insider Own	7.44%	Shs Outstand	1.24M	Perf Week	-1.61%
Market Cap	14.48M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.22M	Perf Month	-11.67%
Income	-16.25M	PEG	-	EPS next Q	-	Inst Own	35.83%	Short Float	1.05%	Perf Quarter	-12.21%
Sales	40.93M	P/S	0.35	EPS this Y	-	Inst Trans	-	Short Ratio	0.87	Perf Half Y	-40.79%
Book/sh	17.76	P/B	0.62	EPS next Y	-	ROA	-29.09%	Short Interest	0.01M	Perf Year	-82.96%
Cash/sh	14.45	P/C	0.76	EPS next 5Y	-	ROE	-86.86%	52W Range	10.60 - 80.80	Perf YTD	-24.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.57%	ROI	-73.99%	52W High	-86.42%	Beta	0.75
Dividend TTM	-	Quick Ratio	3.92	Sales past 5Y	15.45%	Gross Margin	94.47%	52W Low	3.49%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	3.92	EPS Y/Y TTM	71.38%	Oper. Margin	-13.77%	RSI (14)	32.67	Volatility	2.91% 4.94%
Employees	50	Debt/Eq	0.00	Sales Y/Y TTM	142.89%	Profit Margin	-39.71%	Recom	1.67	Target Price	560.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	72.06%	Payout	-	Rel Volume	0.38	Prev Close	11.25
Sales Surprise	-2.50%	EPS Surprise	29.06%	Sales Q/Q	-97.26%	Earnings	-	Avg Volume	14.72K	Price	10.97
SMA20	-4.06%	SMA50	-17.02%	SMA200	-36.23%	Trades		Volume	5,652	Change	-2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform	$5
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform	$5
Mar-19-18	Initiated	Jefferies	Buy	$12
Mar-19-18	Initiated	Evercore ISI	Outperform	$13
Jan-16-18	Reiterated	H.C. Wainwright	Buy	$9 → $12
May-30-17	Initiated	Rodman & Renshaw	Buy	$9
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform	$8
Jul-22-15	Initiated	ROTH Capital	Buy	$7

Show Previous Ratings

Today 02:52PM	PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
May-15-24 05:43PM	Pieris Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
Apr-19-24 12:10PM	Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split (ACCESSWIRE) -6.60%
Mar-27-24 08:00AM	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential (ACCESSWIRE)
Nov-14-23 05:36PM	Pieris Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
12:00PM	Loading…
Sep-25-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why (Zacks)
Aug-24-23 12:32PM	Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis (GuruFocus.com)
Aug-23-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +19.68%
Aug-17-23 08:00AM	Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific (ACCESSWIRE) +8.06%
Jul-19-23 02:02PM	Pieris lays off most staff after AstraZeneca pulls out of partnership (American City Business Journals)
08:40AM	Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises (Zacks)
Jul-18-23 01:59PM	Why Pieris Pharmaceuticals Shares Shooting Higher Today? (Benzinga) +11.81%
09:15AM	Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring (ACCESSWIRE)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks) +12.02%
07:00AM	Loading…
Jun-21-23 07:00AM	Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study (ACCESSWIRE) -70.86%
Jun-11-23 10:28AM	We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate (Simply Wall St.)
Jun-02-23 04:30PM	Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference (ACCESSWIRE) +5.35%
May-22-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference (ACCESSWIRE) +6.00%
May-21-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference (ACCESSWIRE)
May-15-23 06:07AM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 01:41PM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript (Insider Monkey) +10.60%
May-10-23 08:15AM	Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates (ACCESSWIRE)
May-05-23 06:41AM	Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +7.42%
May-04-23 08:00AM	Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) (ACCESSWIRE)
May-02-23 04:30PM	Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023 (ACCESSWIRE)
Apr-17-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting (ACCESSWIRE) +14.89%
Apr-01-23 12:47PM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:10AM	Pieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021) (Simply Wall St.) -5.24%
05:00PM	Loading…
Mar-29-23 05:00PM	Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively (Benzinga) -28.38%
08:35AM	Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates (ACCESSWIRE)
Mar-24-23 05:00PM	Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023 (ACCESSWIRE)
Feb-19-23 07:39AM	Pieris Pharmaceuticals (NASDAQ:PIRS) shareholders have endured a 81% loss from investing in the stock five years ago (Simply Wall St.)
Feb-14-23 05:40AM	Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains? (Zacks)
Jan-17-23 07:10AM	While institutions own 32% of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), individual investors are its largest shareholders with 40% ownership (Simply Wall St.) -16.67%
Jan-10-23 08:00AM	Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346) (ACCESSWIRE) +10.16%
Dec-21-22 06:01AM	Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Could Be Quite Risky (Simply Wall St.)
Nov-23-22 08:00AM	Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference (ACCESSWIRE) +6.26%
Nov-09-22 08:00AM	Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference (ACCESSWIRE) -7.30%
Nov-02-22 08:35AM	Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-01-22 09:15AM	Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220 (ACCESSWIRE)
Oct-26-22 08:00AM	Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022 (ACCESSWIRE)
Sep-12-22 08:03AM	Shareholders in Pieris Pharmaceuticals (NASDAQ:PIRS) are in the red if they invested a year ago (Simply Wall St.)
Sep-08-22 04:01PM	Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Aug-24-22 10:34AM	Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate (Benzinga) +5.33%
08:00AM	Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS (ACCESSWIRE)
Aug-10-22 06:20AM	One Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analyst Is Reducing Their Forecasts For This Year (Simply Wall St.)
Aug-04-22 02:03PM	Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs (Benzinga) -5.49%
09:35AM	Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-28-22 07:20AM	Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022 (ACCESSWIRE)
Jul-14-22 06:29AM	Here's Why We're Not Too Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Situation (Simply Wall St.)
Jun-02-22 08:00AM	Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference (ACCESSWIRE)
May-18-22 09:35AM	Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:00AM	Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference (ACCESSWIRE)
May-16-22 09:35AM	After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS) (Zacks)
08:29AM	How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own? (Simply Wall St.)
May-11-22 08:45AM	Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -20.44%
07:00AM	Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-04-22 08:00AM	Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022 (ACCESSWIRE)
Apr-15-22 11:00AM	3 Risky Stocks With Huge Potential Upside (Motley Fool)
Apr-09-22 06:00AM	This Pharmaceutical Stock Could Be Your Lottery Ticket (Motley Fool)
Apr-08-22 06:15AM	This Pharmaceutical Stock Could Bank Billions Soon (Motley Fool)
Apr-05-22 12:00PM	Pieris Pharmaceuticals' (NASDAQ:PIRS) investors will be pleased with their favorable 34% return over the last five years (Simply Wall St.)
Mar-04-22 04:00PM	Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off. (Motley Fool) -5.47%
Mar-01-22 11:05AM	Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-28-22 09:25AM	Heska (HSKA) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-23-22 08:00AM	Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022 (ACCESSWIRE)
Feb-04-22 08:58AM	Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-28-22 08:00AM	HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors (GlobeNewswire)
Jan-27-22 06:23PM	3 Biotechs That Will Soar Regardless of COVID-19 (Motley Fool) -6.32%
Jan-16-22 10:30AM	2 Risky Growth Stocks That Could Make You Filthy Rich (Motley Fool)
Jan-14-22 08:00AM	Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 41BB/HER2 Bispecific Cinrebafusp Alfa (ACCESSWIRE)
Jan-03-22 07:00AM	Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402 (ACCESSWIRE)
Dec-15-21 12:53PM	Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't? (Zacks)
Dec-06-21 09:33AM	How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own? (Simply Wall St.)
Nov-11-21 08:05AM	Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences (ACCESSWIRE)
Nov-08-21 08:00AM	Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012 (ACCESSWIRE)
Nov-02-21 09:05AM	Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Oct-26-21 08:00AM	Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021 (ACCESSWIRE)
Oct-14-21 10:00AM	2 Penny Stocks That Could Soar Soon (Motley Fool)
Oct-06-21 08:00AM	Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer (ACCESSWIRE)
Sep-09-21 08:00AM	Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences (ACCESSWIRE) +8.99%
Sep-08-21 10:31AM	2 Stocks I Bought Last Week (Motley Fool)
Aug-27-21 10:40AM	Which Biotech Stock Will Shock the Market in 2022? (Motley Fool)
Aug-24-21 09:00AM	Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor (ACCESSWIRE)
Aug-06-21 09:42AM	Party Time: Brokers Just Made Major Increases To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Earnings Forecasts (Simply Wall St.)
Aug-04-21 09:25AM	Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-03-21 08:00AM	Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team (ACCESSWIRE)
Jul-28-21 08:00AM	Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021 (ACCESSWIRE)
Jun-30-21 08:31AM	This Risky Micro-Cap Could Pay Off Big (Motley Fool)
Jun-25-21 09:24AM	Akumin To Acquire Alliance HealthCare Services With An Enterprise Value Of $820M (Benzinga) -8.47%
07:00AM	Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis (ACCESSWIRE)
06:18AM	What Makes Penny Stock Pieris Pharma A Strong Buy? (TipRanks)

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIRITSY CHRISTOPHER P	Director	May 25 '23	Buy	0.85	10,000	8,500	20,000	May 30 04:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PIRS

Pieris Pharmaceuticals Inc

Upgrade your FINVIZ experience